Trial Profile
A Phase III Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Combination With Glucocorticoid Treatment Compared to Glucocorticoid Monotherapy in Adults With Giant Cell Arteritis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Prednisone
- Indications Giant cell arteritis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Jul 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 22 Jun 2017 New trial record